-transparent.png){kind=logo}
A phase I and pharmacokinetic study of tiazofurin (NSC 286193), a C-nucleoside that inhibits IMP dehydrogenase, has been completed. The drug was administered by continuous infusion over 5 days. The maximum tolerated dose was 1650 mg/m2 per day, neurological toxicity being the dose-limiting factor. Gastrointestinal and hematological toxicity were mild. A definite relationship exists between dosage and steady-state levels. The plasma clearance was 29.13 (+/- SD 4.05) ml/min per m2. No complete or partial remissions were demonstrated among the 18 patients treated at five dose levels between 550 mg/m2 and 2200 mg/m2 per day.
Related Publications
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
January 1985,
Investigational new drugs,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
October 1985,
Cancer research,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
June 1985,
Cancer research,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
January 1990,
Investigational new drugs,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
January 1987,
Cancer research,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
February 2002,
Cancer chemotherapy and pharmacology,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
January 1986,
Cancer chemotherapy and pharmacology,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
August 1992,
Investigational new drugs,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
January 1998,
Investigational new drugs,
D Raghavan, and
J Bishop, and
D Sampson, and
J Grygiel, and
R Woods, and
A Coates, and
R Fox
March 1991,
Cancer research,
